CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study

Table 2 Effectiveness of CoronaVac against symptomatic and severe COVID-19, among pregnant women aged 18–49 years in Brazil (comparison of symptomatic and severe cases with test-negative controls)

Sinovac-CoronaVac
Vaccination status	Unadjusted odds ratio (95% CI)	Unadjusted^# odds ratio (95% CI)	Adjusted odds ratio (95% CI)	Adjusted* VE% (95% CI)	p-value
Symptomatic COVID-19
Unvaccinated	Ref	Ref	Ref	Ref
One dose < 13 days	0.94 (0.77–1.14)	1.35 (1.10–1.66)	1.35 (1.09–1.68)	–	0.006
Partially vaccinated (one dose ≥ 14 days)	0.64 (0.53–0.77)	1.00 (0.82–1.22)	0.94 (0.76–1.18)	5.02 (–18.22– 23.69)	0.645
Two doses ≥ 14 days	0.42 (0.35–0.50)	0.69 (0.57–0.83)	0.59 (0.47–0.72)	40.97 (27.07– 52.22)	< 0.001
Severe COVID-19
Unvaccinated	Ref	Ref	Ref	Ref
One dose < 13 days	1.38 (0.87–2.19)	1.64 (1.01–2.65)	1.42 (0.83–2.43)	–	0.192
Partially vaccinated (one dose ≥ 14 days)	0.30 (0.13–0.69)	0.38 (0.16–0.87)	0.32 (0.13–0.80)	67.74 (20.00–87.00)	0.015
Two doses ≥ 14 days	0.15 (0.06–0.37)	0.20 (0.08–0.50)	0.14 (0.05–0.40)	85.39 (59.44– 94.80)	< 0.001

ISSN: 1741-7015